1. Home
  2. RYTM vs ECG Comparison

RYTM vs ECG Comparison

Compare RYTM & ECG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • ECG
  • Stock Information
  • Founded
  • RYTM 2008
  • ECG 1995
  • Country
  • RYTM United States
  • ECG United States
  • Employees
  • RYTM N/A
  • ECG N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • ECG
  • Sector
  • RYTM Health Care
  • ECG
  • Exchange
  • RYTM Nasdaq
  • ECG NYSE
  • Market Cap
  • RYTM 3.5B
  • ECG 3.5B
  • IPO Year
  • RYTM 2017
  • ECG N/A
  • Fundamental
  • Price
  • RYTM $56.07
  • ECG $43.58
  • Analyst Decision
  • RYTM Strong Buy
  • ECG Strong Buy
  • Analyst Count
  • RYTM 10
  • ECG 2
  • Target Price
  • RYTM $66.90
  • ECG $73.50
  • AVG Volume (30 Days)
  • RYTM 380.5K
  • ECG 780.3K
  • Earning Date
  • RYTM 02-26-2025
  • ECG 02-11-2025
  • Dividend Yield
  • RYTM N/A
  • ECG N/A
  • EPS Growth
  • RYTM N/A
  • ECG N/A
  • EPS
  • RYTM N/A
  • ECG 2.81
  • Revenue
  • RYTM $112,530,000.00
  • ECG $2,849,685,000.00
  • Revenue This Year
  • RYTM $66.58
  • ECG $4.22
  • Revenue Next Year
  • RYTM $44.63
  • ECG $5.79
  • P/E Ratio
  • RYTM N/A
  • ECG $15.51
  • Revenue Growth
  • RYTM 81.55
  • ECG N/A
  • 52 Week Low
  • RYTM $35.17
  • ECG $40.05
  • 52 Week High
  • RYTM $68.58
  • ECG $77.93
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 42.18
  • ECG N/A
  • Support Level
  • RYTM $56.03
  • ECG N/A
  • Resistance Level
  • RYTM $58.65
  • ECG N/A
  • Average True Range (ATR)
  • RYTM 1.87
  • ECG 0.00
  • MACD
  • RYTM -0.27
  • ECG 0.00
  • Stochastic Oscillator
  • RYTM 5.45
  • ECG 0.00

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.

About ECG EVERUS CONSTRUCTION GROUP INC

Everus Construction Group Inc is a construction solutions provider, offering specialty contracting services to a diverse set of end markets across the U.S. It operates across two segments, Electrical & Mechanical (E&M) and Transmission & Distribution (T&D), and delivers services through its subsidiaries. It generates the majority of revenue from the Electrical & Mechanical segment which offers a wide variety of specialty contracting services, including construction and maintenance of electrical and communication wiring, fire suppression systems, and mechanical piping and services, to customers in both the public and private sectors. Its T&D segment serves electric and natural gas utility customers, as well as customers in the transportation end market, in the West and Midwest regions.

Share on Social Networks: